Medtech Insight: 世界の医療機器・医療技術の最新情報

US Election 2020: Almost All House Members Backed By Industry PAC Dollars Retain Seats

By Sue Darcey 16 Jun 2022

Out of 31 US House incumbents supported by high amounts of medtech industry political action committee (PAC) dollars, only one – Chrissy Houlahan of Pennsylvania – lost in last week’s election.

Topic us-election-2020 policy-and-regulation Legislation

Generics Bulletin: ジェネリック＆バイオシミラーニュース

California Plans To Create Own Generics Label

By Aidan Fry 27 Nov 2020

California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.

Topic Legislation policy-and-regulation

Medtech Insight: 世界の医療機器・医療技術の最新情報

All About Value – Brexit Aside, UK Industry Sees Good Things Ahead For Healthtech Adoption

27 Nov 2020

ABHI director of value and access Luella Trickett talks about the importance of real-world evidence in product development and value-based procurement in secondary care in the UK.

Topic Medtech-Brexit EU Legislation Regulation

Medtech Insight: 世界の医療機器・医療技術の最新情報

US Election 2020: Industry Loses Three Favored Incumbents In Battle For Senate Control

18 Nov 2020

A few of the US Senate candidates favored and given tens of thousands of dollars by industry have lost their battles for re-election

Topic us-election-2020 Legislation

世界の薬事規制動向＆情報を配信

Biopharma Needs A Deal On Drug Pricing As Shield Against Possible Democrat Wins - BIO's Greenwood

By Cathy Kelly 21 Sep 2020

Outgoing Biotechnology Innovation Organization CEO suggests consideration of price inflation caps instead of 'big discounts' in Medicare Part D and says that industry should fund a cap on beneficiary out-of-pocket costs in the program.

Topic us-election-2020 drug-pricing Legislation

世界の薬事規制動向＆情報を配信

Mylan/Biocon's Insulin Glargine Would Get A Respite Under US Budget Legislation

By Cathy Kelly 18 Dec 2019

Bill addresses ‘dead zone’ for pending applications for protein products transitioning to biologic status; generic and brand industries each win in different legislative provisions: inclusion of the CREATES Act, and a revised definition for ‘biologics’ that includes chemically synthesized polypeptides.

Topic biosimilars Legislation

In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

Outlook 2020 Report

18 Dec 2019

Tap Outlook 2020’s essential coverage of medtech, R&D, clinical trials and regulation, manufacturing, and more with your extract from our most powerful report.

Topic Outlook medtech M A Manufacturing Market Intelligence Regulation Legislation Leadership

HBW Insight : コンシューマーヘルスケア産業のニュース

US Senate Passes First Monograph Reform Bill After House Passed Three

By Malcolm Spicer 11 Dec 2019

Senate's Over-the-Counter Monograph Safety, Innovation, and Reform Act goes next for consideration by House, which has had a bill by the same title on its floor for a vote since it was passed by Energy and Commerce Committee in late June.

Topic fda Legislation OTC Drugs